Anna Nixon, NP
Primary Care · Lees Summit, MONPI 1023600574
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AbbVie at 27.4% of the total. Reporting peaked in 2021 at $770 and has fallen 98.3% since, to $13 in 2024.
Across 69 payments — averaging $15.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$299
- Lilly USA, LLC$130
- Johnson & Johnson$123
- Novo Nordisk$76
- Boehringer Ingelheim$74
- AstraZeneca$71
- plus $320 from 12 others
What the payments were for
- Food & beverage$1,092100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 21 | $299 |
| Lilly USA, LLC | 8 | $130 |
| Johnson & Johnson | 8 | $123 |
| Novo Nordisk | 4 | $76 |
| Boehringer Ingelheim | 5 | $74 |
| AstraZeneca(2 entities) | 4 | $71 |
| Merck | 4 | $64 |
| Novartis | 3 | $43 |
| Mallinckrodt Hospital Products Inc. | 2 | $43 |
| Eisai Inc. | 2 | $41 |
| Seqirus USA Inc | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Biogen | 1 | $16 |
| Vifor Pharma, Inc. | 1 | $15 |
| Amgen | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$1,092 in reported general payments places this provider in the 70th percentile of 106 primary care providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 26 | $187 |
| Cefdinir | 13 | $126 |
| Doxycycline Hyclate | 15 | $70 |
| Methylprednisolone | 11 | $65 |
| Prednisone | 20 | $25 |
Paid to pharmacies, not to this prescriber.
Other primary care in Lees Summit
- Susan GardnerLees Summit$323
- Tabitha BeckLees Summit$240
- Danielle ToalCape Girardeau$15K
- Joy MurphySaint Louis$7K
- Katrina SelsorSparta$6K
- Kelly EspositoSaint Louis$6K
- Elizabeth YoungSaint Louis$5K
- Carol HarringtonIndependence$4K
- Melanie HenryHayti$4K
- Heather BealSaint Louis$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.